Written by Dentistry Today Monday, 10 January 2011 16:03
YORK, Pa., Jan. 7, 2011 (GLOBE NEWSWIRE) -- GlaxoSmithKline (GSK) and DENTSPLY International (Nasdaq:XRAY), a global leader in professional dental products, today announced that they have entered into an agreement to create a portfolio of co-branded oral care products to be used in the dental office by patients suffering from tooth sensitivity, a problem which is estimated to affect 1 in 3 people.
In December 2009, GSK acquired NovaMin(R) through the purchase of NovaMin Technology Inc. NovaMin(R) is a patent protected innovative calcium phosphate technology which has been clinically proven to relieve tooth sensitivity. Today's agreement will allow DENTSPLY to co-brand its NUPRO(R) products which contain the NovaMin(R) technology, with GSK's Sensodyne(R) brand. This co-branding will provide a continuum of care for tooth sensitivity treatment from the dental office to everyday use at home.